Clinical characteristics of patients with psychotic disorders and control subjects*
| Characteristic | Patients with psychosis | Control subjects | p Value |
|---|---|---|---|
| Number of participants | 977† | 3908 | |
| Sex, men | 528 (54) | 1620 (41) | 0.001 |
| Age (years) | 47 (18–84) | 56 (43–66) | 0.001 |
| Waist circumference (cm) | 102 (63–156) | 89 (62–141) | 0.001 |
| Men | 105 (69–151) | 95 (63–141) | 0.001 |
| Women | 98 (63–156) | 84 (62–131) | 0.001 |
| BMI | 29 (11.2–65.8) | 26 (16.4–53.7) | |
| Current smoker | 397 (41) | 666 (17) | 0.001 |
| Family history of diabetes | 184 (24) | 956 (24) | 0.880 |
| Fasting glucose (mmol/L)‡ | 5.6 (3.5–20.1) | 5.0 (2.8–14.7) | 0.001 |
| Triglycerides ≥1.7 mmol/L | 400 (41) | ND | – |
| Reduced HDL levels§ | 431 (44) | ND | – |
| Metabolic syndrome | 432 (45) | ND | – |
| Antihypertensive medication | 84 (9) | 693 (18) | |
| Psychiatric diagnosis | |||
| Schizophrenia | 526 (54) | NA | – |
| Psychosis NOS | 120 (12) | NA | – |
| Schizoaffective disorder | 110 (11) | NA | – |
| Delusional disorder | 63 (6) | NA | – |
| Bipolar disorder | 64 (7) | NA | – |
| Other psychiatric diagnosis | 90 (9) | NA | – |
| Antipsychotic drug | 769 (79) | ||
| Long-acting injectable | 192 (24) | NA | |
| Risperidone | 135 (14) | NA | |
| Olanzapine | 130 (13) | 2 (0.05) | |
| Clozapine | 72 (7) | NA | |
| Aripiprazole | 58 (6) | NA |
*Data reported as number, number (%), or mean (range, minimum–maximum).
†Number of patients varied due to sporadic missing information.
‡Patients withpsychosis and control subjects with no antidiabetic medication.
§HDL level <1.0 mmol/L (males) or <1.3 mmol/L (females) or lipid-lowering medication.
BMI, body mass index; HDL, high-density lipoprotein; NA, not applicable; ND, not determined; NOS, not otherwise specified.